RMD Open publishes high quality peer-reviewed original research covering the full spectrum of musculoskeletal disorders, rheumatism and connective tissue diseases, including osteoporosis, spine and rehabilitation.Clinical and epidemiological research, basic and translational medicine, interesting clinical cases, and smaller studies that add to the literature are all considered.

RMD Open is an open access journal and levies an Article Processing Charge (APC) of 2,275 GBP (exclusive of VAT for UK and EU authors). The APC for Letters is 1,140 GBP. There are no submission, colour or page charges. There is a 25% discount for articles where the corresponding author has reviewed for RMD Open within the previous 12 months. A 50% discount on the standard APC will apply to ...

Web of Science Core Collection: Science Citation Index Expanded; Emerging Sources Citation Index, Current Contents: Clinical Medicine, MEDLINE (Index Medicus), PubMed Central, Scopus, Embase (Excerpta Medica), DOAJ, Google Scholar

Correction: Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long- term extension study (27 January, 2025) Correction: Efficacy and safety of jaktinib hydrochloride tablets in active axial spondyloarthritis: a multicentre, randomised, double ...

Edited by Annette van der Helm-van Mil and Karim Raza Over the last decade the outlook for patients with Rheumatoid Arthritis (RA) has improved, but there is growing interest in preventing RA by treating individuals in the pre-arthritic phase. While clinical trials in people at risk for RA have shown promise, key questions remain. RMD Open is calling for submissions on the mechanisms driving ...

Background We aimed to update the 2018 systematic literature review on the efficacy and safety of treatments for hand osteoarthritis (OA), which was based on 126 studies. Methods We performed a systematic literature search on randomised controlled trials from June 2017 up to 31 December 2023. Risk of bias was assessed using the RoB2 tool. Meta-analyses of previous and new studies regarding the ...

An open access rheumatology journal publishing research on rheumatic and musculoskeletal disorders and connective tissue diseases. An official journal of EULAR.

Background The REDO trial (REtreatment with Rituximab in RhEmatoid arthritis: Disease Outcome after Dose Optimisation) showed similar disease activity for retreatment with ultralow doses (200 mg and 500 mg per 6 months) compared with standard low-dose rituximab (RTX, 1000 mg per 6 months). We performed an observational extension study of the REDO trial to assess long-term effectiveness.

Please see the instructions for authors for submission requirements for each article type. To submit your article, please follow these instructions and select ‘Pre-arthritis stages of Rheumatoid Arthritis: from Pathology to Disease Prevention’ as the Topic Collection.All submitted articles will be subject to the journal's normal peer review process.

Background Janus kinase inhibitors are an effective option for achieving sustained remission or low disease activity in patients with rheumatoid arthritis (RA) following inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs. Filgotinib is a Janus kinase 1–preferential inhibitor available in two doses for moderate-to …